A mouse DCM model was used to demonstrate that dapagliflozin prevents ventricular dilatation and improves cardiac function by reducing toll-like receptor 4 expression and inhibiting nucleotide-binding oligomerization domain-like receptor family protein 3 inflammasome pathway activation.[12] In human tubular epithelial cells, SGLT2 inhibitors remarkably reversed glucose-induced reducing toll-like receptor 4expression.[22] So, we speculated that SGLT2 inhibitors reduce cardiac dilation and remodeling and improve cardiac function in DCM patients through its anti-inflammatory effects. The gene discussed is SLC5A2; the disease is Ventriculomegaly.